Location Philadelphia, Pennsylvania, United States Regions Greater Philadelphia Area, Great Lakes, Northeastern US Gender Female
Website www.cabalettabio.com/ LinkedIn View on LinkedIn
Aimee Payne, MD, PhD, is co-founder and co-chair of the Scientific Advisory Board at Cabaletta Bio, a biopharmaceutical company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases. She received her BS degree in Biology from Stanford University and her MD/PhD degree in Molecular and Cellular
Biology at Washington University School of Medicine, followed by dermatology residency training at the University of Pennsylvania. Dr. Payne is currently the Albert M. Kligman Associate Professor of Dermatology and lead physician in the Autoimmune Blistering Clinic at the University of Pennsylvania. Her research laboratory has contributed to three major areas of investigation: 1) cloning and characterization of B cell repertoires to understand how autoimmunity occurs in pemphigus, a model autoantibody-mediated skin blistering disease; 2) cell biologic studies to understand mechanisms for loss of cell adhesion; and 3) clinical-translational research to better understand current diagnostic tests and treatments and to develop novel targeted therapies for disease. Her laboratory pioneered the chimeric autoantibody receptor (CAAR) T cell therapy concept for targeted depletion of autoreactive B cells that forms the foundation for Cabaletta Bio.
